The DOI matches its Crossref record; 399 of the 399 references it cites were found in a registry or an index.
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease
Open accessAbstract
Animal models of Parkinson's disease (PD) have proved highly effective in the discovery of novel treatments for motor symptoms of PD and in the search for clues to the underlying cause of the illness. Models based on specific pathogenic mechanisms may subsequently lead to the development of neuroprotective agents for PD that stop or slow disease progression. The array of available rodent models is large and ranges from acute pharmacological models, such as the reserpine‐ or haloperidol‐treated rats that display one or more parkinsonian signs, to models exhibiting destruction of the dopaminergic nigro‐striatal pathway, such as the classical 6‐hydroxydopamine (6‐OHDA) rat and 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP) mouse models. All of these have provided test beds in which new molecules for treating the motor symptoms of PD can be assessed. In addition, the emergence of abnormal involuntary movements (AIMs) with repeated treatment of 6‐OHDA‐lesioned rats with L‐DOPA has allowed for examination of the mechanisms responsible for treatment‐related dyskinesia in PD, and the detection of molecules able to prevent or reverse their appearance. Other toxin‐based models of nigro‐striatal tract degeneration include the systemic administration of the pesticides rotenone and paraquat, but whilst providing clues to disease pathogenesis, these are not so commonly used for drug development. The MPTP‐treated primate model of PD, which closely mimics the clinical features of PD and in which all currently used anti‐parkinsonian medications have been shown to be effective, is undoubtedly the most clinically‐relevant of all available models. The MPTP‐treated primate develops clear dyskinesia when repeatedly exposed to L‐DOPA, and these parkinsonian animals have shown responses to novel dopaminergic agents that are highly predictive of their effect in man. Whether non‐dopaminergic drugs show the same degree of predictability of response is a matter of debate. As our understanding of the pathogenesis of PD has improved, so new rodent models produced by agents mimicking these mechanisms, including proteasome inhibitors such as PSI, lactacystin and epoximycin or inflammogens like lipopolysaccharide (LPS) have been developed. A further generation of models aimed at mimicking the genetic causes of PD has also sprung up. Whilst these newer models have provided further clues to the disease pathology, they have so far been less commonly used for drug development. There is little doubt that the availability of experimental animal models of PD has dramatically altered dopaminergic drug treatment of the illness and the prevention and reversal of drug‐related side effects that emerge with disease progression and chronic medication. However, so far, we have made little progress in moving into other pharmacological areas for the treatment of PD, and we have not developed models that reflect the progressive nature of the illness and its complexity in terms of the extent of pathology and biochemical change. Only when this occurs are we likely to make progress in developing agents to stop or slow the disease progression. The overarching question that draws all of these models together in the quest for better drug treatments for PD is how well do they recapitulate the human condition and how predictive are they of successful translation of drugs into the clinic? This article aims to clarify the current position and highlight the strengths and weaknesses of available models. LINKED ARTICLES This article is part of a themed issue on Translational Neuropharmacology. To view the other articles in this issue visit http://dx.doi.org/10.1111/bph.2011.164.issue‐4
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382 · cited 1×
“Lewy bodies are eosinophilic inclusions that contain ubiquitinated proteins such as a-synuclein (Spillantini et al., 1997; Baba et al., 1998) and are associated with lipofuscin-containing lysosomes that have also been shown to accumulate a-synuclein in PD brain stem (Braak et al., 2001).”
BackgroundMutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240 · cited 1×
“Interest in Lewy body formation was rekindled by the discovery of mutations in a-synuclein responsible for rare forms of familial PD (Polymeropoulos et al., 1997).”
BackgroundMutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227 · cited 1×
“The subsequent discovery of two further mutations in familial PD, namely ubiquitin carboxy terminal hydrolase-1 (UCH-L1) and parkin, that affect the functioning of the ubiquitin– proteasome system, further focused attention (Kitada et al., 1998; Leroy et al., 1998).”
BackgroundChronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V., & Greenamyre, J. T. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,683
Frequency Dependence of Signal Power and Spatial Reach of the Local Field Potential
Leski, S., Lindén, H., Tetzlaff, T., Pettersen, K. H., & Einevoll, G. T. (2013) · PubMed · doi:10.18154/rwth-conv-084442 · Cited by 3,639
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., & Goedert, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6469 · Cited by 2,868
Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M., & Kopin, I. J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.14.4546 · Cited by 2,149
Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration
Qin, L., Wu, X., Block, M. L., Liu, Y., Breese, G. R., Hong, J., Knapp, D. J., & Crews, F. T. (2007) · Glia · doi:10.1002/glia.20467 · Cited by 2,144 · cited 1×
“Interestingly, a single administration of LPS given to adult mice has been reported to cause progressive dopaminergic neuronal loss (Qin et al., 2007).”
BackgroundMulticenter Analysis of Glucocerebrosidase Mutations in Parkinson's Disease
Sidransky, E., Nalls, M. A., Aasly, J. O., Aharon-Peretz, J., Annesi, G., Barbosa, E. R., Bar-Shira, A., Berg, D., Bras, J., Brice, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901281 · Cited by 2,135
A Drosophila model of Parkinson's disease
Feany, M. B., & Bender, W. W. (2000) · Nature · doi:10.1038/35006074 · Cited by 2,118
Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin
Park, J., Lee, S. B., Lee, S., Kim, Y., Song, S., Kim, S., Bae, E., Kim, J., Shong, M., Kim, J.-M., et al. (2006) · Nature · doi:10.1038/nature04788 · Cited by 1,705 · cited 2×
“PINK1 inactivation in Drosophila also leads to reduced numbers of dopaminergic neurons and impaired climbing ability (Park et al., 2006; Wang et al., 2006a), whilst DJ-1 mutant Drosophila do not produce a consistent PD-like phenotype (Park et al., 2005).”
Background(1998) · Europe PMC (PubMed Central) · Cited by 1,594
The ubiquitin pathway in Parkinson's disease
Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., Harta, G., Brownstein, M. J., Jonnalagada, S., Chernova, T., et al. (1998) · Nature · doi:10.1038/26652 · Cited by 1,571
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
6-hydroxy-dopamine induced degeneration of central monoamine neurons
Ungerstedt, U. (1968) · European Journal of Pharmacology · doi:10.1016/0014-2999(68)90164-7 · Cited by 1,460
Chronic parkinsonism secondary to intravenous injection of meperidine analogues
Davis, G. C., Williams, A. C., Markey, S. P., Ebert, M. H., Caine, E. D., Reichert, C. M., & Kopin, I. J. (1979) · Psychiatry Research · doi:10.1016/0165-1781(79)90006-4 · Cited by 1,376
Functional Repression of cAMP Response Element in 6-Hydroxydopamine-treated Neuronal Cells
Chalovich, E. M., Zhu, J.-H., Caltagarone, J., Bowser, R., & Chu, C. T. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602632200 · Cited by 1,371
Schallert, T., Fleming, S. M., Leasure, J. L., Tillerson, J. L., & Bland, S. T. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(00)00005-8 · Cited by 1,354
3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists
CARLSSON, A., LINDQVIST, M., & MAGNUSSON, T. (1957) · Nature · doi:10.1038/1801200a0 · Cited by 1,278
Javitch, J. A., D'Amato, R. J., Strittmatter, S. M., & Snyder, S. H. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.7.2173 · Cited by 1,263
Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease
Auluck, P. K., Chan, H. Y. E., Trojanowski, J. Q., Lee, V. M.-Y., & Bonini, N. M. (2002) · Science · doi:10.1126/science.1067389 · Cited by 1,227 · cited 1×
“Some later studies confirmed an ~50% loss of dopaminergic neurons in 20 day-old flies (Auluck et al., 2002), although others failed to pick out any losses, possibly due to the reduced sensitivity of using whole-mount immunohistochemistry techniques (Pesah et al., 2005).”
BackgroundMitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants
Greene, J. C., Whitworth, A. J., Kuo, I., Andrews, L. A., Feany, M. B., & Pallanck, L. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0737556100 · Cited by 1,203
In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200 · cited 3×
“…microglial activation seen in both the SNpc and striatum following rotenone infusion (Sherer et al., 2003b) is consistent with the inflammatory features found in idiopathic PD (Gerhard et al., 2006; Whitton, 2007; Tansey and Goldberg, 2010), lending support to the construct validity of this model.”
ResultProtocol for the MPTP mouse model of Parkinson's disease
Jackson-Lewis, V., & Przedborski, S. (2007) · Nature Protocols · doi:10.1038/nprot.2006.342 · Cited by 1,111
Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase
Chiba, K., Trevor, A., & Castagnoli, N. (1984) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(84)91293-2 · Cited by 1,097
Dopamine Neuron Agenesis in Nurr1-Deficient Mice
Zetterström, R. H., Solomin, L., Jansson, L., Hoffer, B. J., Olson, L., & Perlmann, T. (1997) · Science · doi:10.1126/science.276.5310.248 · Cited by 1,092
Sawin, E. R., Ranganathan, R., & Horvitz, H. R. (2000) · Neuron · doi:10.1016/s0896-6273(00)81199-x · Cited by 1,076
Mechanism of Toxicity in Rotenone Models of Parkinson's Disease
Sherer, T. B., Betarbet, R., Testa, C. M., Seo, B. B., Richardson, J. R., Kim, J. H., Miller, G. W., Yagi, T., Matsuno-Yagi, A., & Greenamyre, J. T. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-34-10756.2003 · Cited by 1,072
Tansey, M. G., & Goldberg, M. S. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.11.004 · Cited by 1,045
Mogi, M., Harada, M., Riederer, P., Narabayashi, H., Fujita, K., & Nagatsu, T. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90746-3 · Cited by 986
William Langston, J., Forno, L. S., Rebert, C. S., & Irwin, I. (1984) · Brain Research · doi:10.1016/0006-8993(84)90777-7 · Cited by 922
FRONTAL LOBE DYSFUNCTION IN PARKINSON'S DISEASE: THE CORTICAL FOCUS OF NEOSTRIATAL OUTFLOW
TAYLOR, A. E., SAINT-CYR, J. A., & LANG, A. E. (1986) · Brain · doi:10.1093/brain/109.5.845 · Cited by 882
Pathophysiology of the basal ganglia in Parkinson's disease
Obeso, J. A., Rodriguez-Oroz, M. C., Rodriguez, M., Lanciego, J. L., Artieda, J., Gonzalo, N., & Olanow, C. W. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00028-8 · Cited by 844
Genetic Animal Models of Parkinson's Disease
Dawson, T. M., Ko, H. S., & Dawson, V. L. (2010) · Neuron · doi:10.1016/j.neuron.2010.04.034 · Cited by 823
Sauer, H., & Oertel, W. H. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90605-x · Cited by 803
Pramipexole vs Levodopa as initial treatment for Parkinson disease: A randomized controlled trial
Holloway, R. G., Shoulson, I., Kieburtz, K. D., McDermott, M., Tariot, P. N., Kamp, C., Day, D., Shinaman, A., Fahn, S., Lang, A. E., et al. (2000) · JAMA · Cited by 798
A highly reproducible rotenone model of Parkinson's disease
Cannon, J. R., Tapias, V., Na, H. M., Honick, A. S., Drolet, R. E., & Greenamyre, J. T. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.01.016 · Cited by 795
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A Randomized Controlled Trial
Parkinson Study Group (2000) · JAMA · doi:10.1001/jama.284.15.1931 · Cited by 767
Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain.
Young, W. S., Bonner, T. I., & Brann, M. R. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.24.9827 · Cited by 743
Sherer, T. B., Kim, J.-H., Betarbet, R., & Greenamyre, J. T. (2003) · Experimental Neurology · doi:10.1006/exnr.2002.8072 · Cited by 708
Neurophysiological identification of the subthalamic nucleus in surgery for Parkinson's disease
Hutchison, W. D., Allan, R. J., Opitz, H., Levy, R., Dostrovsky, J. O., Lang, A. E., & Lozano, A. M. (1998) · Annals of Neurology · doi:10.1002/ana.410440407 · Cited by 702
Glial reactions in Parkinson's disease
McGeer, P. L., & McGeer, E. G. (2008) · Movement Disorders · doi:10.1002/mds.21751 · Cited by 701 · cited 3×
“…to a reactive microgliosis that can persist long after toxin administration and that has been suggested to reflect an on-going loss of dopaminergic neurons that also occurred in MPTP exposed drug addicts (Langston et al., 1999; McGeer et al., 2003; Barcia et al., 2004; McGeer and McGeer, 2008).”
BackgroundPathology of Parkinson’s disease: Changes other than the nigrostriatal pathway
Jellinger, K. A. (1991) · Molecular and Chemical Neuropathology · doi:10.1007/bf03159935 · Cited by 684
Marks, W. J., Bartus, R. T., Siffert, J., Davis, C. S., Lozano, A., Boulis, N., Vitek, J., Stacy, M., Turner, D., Verhagen, L., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70254-4 · Cited by 684
Lundblad, M., Andersson, M., Winkler, C., Kirik, D., Wierup, N., & Cenci, M. A. (2002) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01843.x · Cited by 664
Functional organization of the basal ganglia: Therapeutic implications for Parkinson's disease
Obeso, J. A., Rodríguez-Oroz, M. C., Benitez-Temino, B., Blesa, F. J., Guridi, J., Marin, C., & Rodriguez, M. (2008) · Movement Disorders · doi:10.1002/mds.22062 · Cited by 663
Kirik, D., Rosenblad, C., & Björklund, A. (1998) · Experimental Neurology · doi:10.1006/exnr.1998.6848 · Cited by 663
Proteasomal function is impaired in substantia nigra in Parkinson’s disease
McNaught, K. S. P., & Jenner, P. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01701-8 · Cited by 653
Self-citationKirik, D., Rosenblad, C., Burger, C., Lundberg, C., Johansen, T. E., Muzyczka, N., Mandel, R. J., & Björklund, A. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-07-02780.2002 · Cited by 649
Cenci, M. A., Lee, C. S., & Björklund, A. (1998) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1998.00285.x · Cited by 641
Olsson, M., Nikkhah, G., Bentlage, C., & Bjorklund, A. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-05-03863.1995 · Cited by 625
Inflammation as a causative factor in the aetiology of Parkinson's disease
Whitton, P. S. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707167 · Cited by 624
Jackson-Lewis, V., Jakowec, M., Burke, R. E., & Przedborski, S. (1995) · Neurodegeneration · doi:10.1016/1055-8330(95)90015-2 · Cited by 609
Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589 · cited 2×
“However, there is continued activity in progress based on established animal models, and it will be interesting to see if the neuroprotective/neurorestorative effects of isradipine, exendin or cogane, which have all shown efficacy in the MPTP mouse or 6-OHDA-lesioned rat models (Harkavyi and Whitton, 2010; Li et al.,…”
BackgroundCostello, S., Cockburn, M., Bronstein, J., Zhang, X., & Ritz, B. (2009) · American Journal of Epidemiology · doi:10.1093/aje/kwp006 · Cited by 581
Gibb, W. R., & Lees, A. J. (1991) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.54.5.388 · Cited by 574
Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease
McNaught, K. S. P., Perl, D. P., Brownell, A., & Olanow, C. W. (2004) · Annals of Neurology · doi:10.1002/ana.20186 · Cited by 548
Alam, Z. I., Daniel, S. E., Lees, A. J., Marsden, D. C., Jenner, P., & Halliwell, B. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69031326.x · Cited by 547
Self-citationMotor fluctuations and dyskinesias in Parkinson's disease: Clinical manifestations
Jankovic, J. (2005) · Movement Disorders · doi:10.1002/mds.20458 · Cited by 547
Impaired dopamine release and synaptic plasticity in the striatum of PINK1 -deficient mice
Kitada, T., Pisani, A., Porter, D. R., Yamaguchi, H., Tscherter, A., Martella, G., Bonsi, P., Zhang, C., Pothos, E. N., & Shen, J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702717104 · Cited by 540
Goldberg, M. S., Pisani, A., Haburcak, M., Vortherms, T. A., Kitada, T., Costa, C., Tong, Y., Martella, G., Tscherter, A., Martins, A., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.01.041 · Cited by 538
Fornai, F., Schlüter, O. M., Lenzi, P., Gesi, M., Ruffoli, R., Ferrucci, M., Lazzeri, G., Busceti, C. L., Pontarelli, F., Battaglia, G., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409713102 · Cited by 526
Pan-Montojo, F., Anichtchik, O., Dening, Y., Knels, L., Pursche, S., Jung, R., Jackson, S., Gille, G., Spillantini, M. G., Reichmann, H., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008762 · Cited by 524
Lin, X., Parisiadou, L., Gu, X.-L., Wang, L., Shim, H., Sun, L., Xie, C., Long, C.-X., Yang, W.-J., Ding, J., et al. (2009) · Neuron · doi:10.1016/j.neuron.2009.11.006 · Cited by 518
Przedborski, S., Jackson‐Lewis, V., Naini, A. B., Jakowec, M., Petzinger, G., Miller, R., & Akram, M. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00183.x · Cited by 507
Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies
Bezard, E., Brotchie, J. M., & Gross, C. E. (2001) · Nature Reviews Neuroscience · doi:10.1038/35086062 · Cited by 503
Bezard, E., Dovero, S., Prunier, C., Ravenscroft, P., Chalon, S., Guilloteau, D., Crossman, A. R., Bioulac, B., Brotchie, J. M., & Gross, C. E. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-17-06853.2001 · Cited by 483
Levodopa motor complications in Parkinson's disease
Obeso, J. A., Olanow, C. W., & Nutt, J. G. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00031-8 · Cited by 478
Parkin-deficient mice are not a robust model of parkinsonism
Perez, F. A., & Palmiter, R. D. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409598102 · Cited by 477
Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats
Alam, M., & Schmidt, W. J. (2002) · Behavioural Brain Research · doi:10.1016/s0166-4328(02)00180-8 · Cited by 473
Tatton, N. A., & Kish, S. J. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00545-3 · Cited by 468
Przedbroski, S., Leviver, M., Jiang, H., Ferreira, M., Jackson-Lewis, V., Donaldson, D., & Togasaki, D. M. (1995) · Neuroscience · doi:10.1016/0306-4522(95)00066-r · Cited by 453
The Role of Glial Reaction and Inflammation in Parkinson's Disease
HIRSCH, E. C., BREIDERT, T., ROUSSELET, E., HUNOT, S., HARTMANN, A., & MICHEL, P. P. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb07478.x · Cited by 449
Pesticide exposure and risk for Parkinson's disease
Ascherio, A., Chen, H., Weisskopf, M. G., O'Reilly, E., McCullough, M. L., Calle, E. E., Schwarzschild, M. A., & Thun, M. J. (2006) · Annals of Neurology · doi:10.1002/ana.20904 · Cited by 445
Behavioral phenotyping of the MPTP mouse model of Parkinson's disease
Sedelis, M., Schwarting, R. K. W., & Huston, J. P. (2001) · Behavioural Brain Research · doi:10.1016/s0166-4328(01)00309-6 · Cited by 432
Whitworth, A. J., Theodore, D. A., Greene, J. C., Beneš, H., Wes, P. D., & Pallanck, L. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501078102 · Cited by 422
Chronic Exposure to Rotenone Models Sporadic Parkinson's Disease in Drosophila melanogaster
Coulom, H., & Birman, S. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.2993-04.2004 · Cited by 421
Neurotoxin-induced degeneration of dopamine neurons in Caenorhabditis elegans
Nass, R., Hall, D. H., Miller, D. M., & Blakely, R. D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.042497999 · Cited by 417
Cicchetti, F., Brownell, A. L., Williams, K., Chen, Y. I., Livni, E., & Isacson, O. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.01938.x · Cited by 406
Kirik, D., Annett, L. E., Burger, C., Muzyczka, N., Mandel, R. J., & Björklund, A. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0536383100 · Cited by 403
McGeer, P. L., Schwab, C., Parent, A., & Doudet, D. (2003) · Annals of Neurology · doi:10.1002/ana.10728 · Cited by 400 · cited 2×
“…to a reactive microgliosis that can persist long after toxin administration and that has been suggested to reflect an on-going loss of dopaminergic neurons that also occurred in MPTP exposed drug addicts (Langston et al., 1999; McGeer et al., 2003; Barcia et al., 2004; McGeer and McGeer, 2008).”
BackgroundMidbrain dopaminergic cell loss in parkinson's disease: Computer visualization
German, D. C., Manaye, K., Smith, W. K., Woodward, D. J., & Saper, C. B. (1989) · Annals of Neurology · doi:10.1002/ana.410260403 · Cited by 396
Herrera, A. J., Castaño, A., Venero, J. L., Cano, J., & Machado, A. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0289 · Cited by 392
Pitx3 is required for development of substantia nigra dopaminergic neurons
Nunes, I., Tovmasian, L. T., Silva, R. M., Burke, R. E., & Goff, S. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0230529100 · Cited by 385
Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function
Bézard, E., Ferry, S., Mach, U., Stark, H., Leriche, L., Boraud, T., Gross, C., & Sokoloff, P. (2003) · Nature Medicine · doi:10.1038/nm875 · Cited by 383
Mechanism of 6-hydroxydopamine neurotoxicity
Glinka, Y., Gassen, M., & Youdim, M. B. H. (1997) · Journal of Neural Transmission. Supplementa · doi:10.1007/978-3-7091-6842-4_7 · Cited by 380
Kurkowska-Jastrzębska, I., Wrońska, A., Kohutnicka, M., Członkowski, A., & Członkowska, A. (1999) · Experimental Neurology · doi:10.1006/exnr.1998.6993 · Cited by 379
Hudson, J. L., van Horne, C. G., Strömberg, I., Brock, S., Clayton, J., Masserano, J., Hoffer, B. J., & Gerhardt, G. A. (1993) · Brain Research · doi:10.1016/0006-8993(93)90576-9 · Cited by 377
The catalepsy test: Its ups and downs.
Sanberg, P. R., Bunsey, M. D., Giòrdano, M., & Norman, A. B. (1988) · Behavioral Neuroscience · doi:10.1037//0735-7044.102.5.748 · Cited by 375
Vila, M., Jackson-Lewis, V., Vukosavic, S., Djaldetti, R., Liberatore, G., Offen, D., Korsmeyer, S. J., & Przedborski, S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051633998 · Cited by 372
Locus ceruleus lesions and eosinophilic inclusions in MPTP‐treated monkeys
Forno, L. S., Langston, J. W., DeLanney, L. E., Irwin, I., & Ricaurte, G. A. (1986) · Annals of Neurology · doi:10.1002/ana.410200403 · Cited by 350
Does levodopa slow or hasten the rate of progression of Parkinson’s disease?
Fahn, S., & and the Parkinson Study Group (2005) · Journal of Neurology · doi:10.1007/s00415-005-4008-5 · Cited by 347
Hassani, O.-K., Mouroux, M., & Féger, J. (1996) · Neuroscience · doi:10.1016/0306-4522(95)00535-8 · Cited by 345
Intraoperative microrecordings of the subthalamic nucleus in Parkinson's disease
Benazzouz, A., Breit, S., Koudsie, A., Pollak, P., Krack, P., & Benabid, A.-L. (2002) · Movement Disorders · doi:10.1002/mds.10156 · Cited by 338
Chronic systemic complex I inhibition induces a hypokinetic multisystem degeneration in rats
Höglinger, G. U., Féger, J., Prigent, A., Michel, P. P., Parain, K., Champy, P., Ruberg, M., Oertel, W. H., & Hirsch, E. C. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01533.x · Cited by 331
Petroske, E., Meredith, G. E., Callen, S., Totterdell, S., & Lau, Y.-S. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00295-0 · Cited by 331
Bedford, L., Hay, D., Devoy, A., Paine, S., Powe, D. G., Seth, R., Gray, T., Topham, I., Fone, K., Rezvani, N., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2218-08.2008 · Cited by 327 · cited 1×
“In addition, mice with discrete deletions in proteasomal subunit proteins are also available, and these do exhibit loss of dopaminergic neurons but the life span of these animals seems extremely short (Bedford et al., 2008).”
BackgroundThe role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease
Jankovic, J., Chen, S., & Le, W. D. (2005) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2005.09.001 · Cited by 325
Thiruchelvam, M., Brockel, B. J., Richfield, E. K., Baggs, R. B., & Cory-Slechta, D. A. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02496-3 · Cited by 324
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset
Jenner, P. G., Rupniak, N. M. J., Rose, S., Kelly, E., Kilpatrick, G. J., Lees, A. J., & MARSDEN, C. D. (1984) · Neuroscience Letters · doi:10.1016/0304-3940(84)90467-1 · Cited by 323
Self-citationGERMAN, D. C., MANAYE, K. F., SONSALLA, P. K., & BROOKS, B. A. (1992) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1992.tb24523.x · Cited by 318
Selective microglial activation in the rat rotenone model of Parkinson's disease
Sherer, T. B., Betarbet, R., Kim, J.-H., & Greenamyre, J. T. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00172-1 · Cited by 316
Cicchetti, F., Drouin-Ouellet, J., & Gross, R. E. (2009) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.06.005 · Cited by 311
Haloperidol-induced catalepsy is mediated by postsynaptic dopamine receptors
Sanberg, P. R. (1980) · Nature · doi:10.1038/284472a0 · Cited by 308
Sensitivity of zebrafish to environmental toxins implicated in Parkinson's disease
Bretaud, S., Lee, S., & Guo, S. (2004) · Neurotoxicology and Teratology · doi:10.1016/j.ntt.2004.06.014 · Cited by 305
McNaught, K. S. P., Mytilineou, C., JnoBaptiste, R., Yabut, J., Shashidharan, P., Jenner, P., & Olanow, C. W. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00821.x · Cited by 304
Self-citationMPTP induces alpha-synuclein aggregation in the substantia nigra of baboons
Kowall, N. W., Hantraye, P., Brouillet, E., Beal, M. F., McKee, A. C., & Ferrante, R. J. (2000) · NeuroReport · doi:10.1097/00001756-200001170-00041 · Cited by 291
6-Hydroxydopamine Lesion of the Rat Substantia Nigra: Time Course and Morphology of Cell Death
Jeon, B. S., Jackson-Lewis, V., & Burke, R. E. (1995) · Neurodegeneration · doi:10.1006/neur.1995.0016 · Cited by 289
Differential neuronal activity in segments of globus pallidus in Parkinsonʼs disease patients
Hutchison, W. D., Lozano, A. M., Davis, K. D., Saint-Cyr, J. A., Lang, A. E., & Dostrovsky, J. O. (1994) · NeuroReport · doi:10.1097/00001756-199407000-00031 · Cited by 282
Crossman, A. R. (1987) · Neuroscience · doi:10.1016/0306-4522(87)90322-8 · Cited by 282
William Langston, J., & Ballard, P. (1984) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100046333 · Cited by 281
Hallman, H., Lange, L., Olson, L., Strömberg, I., & Jonsson, G. (1985) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1985.tb07120.x · Cited by 281
A Drosophila model for LRRK2 -linked parkinsonism
Liu, Z., Wang, X., Yu, Y., Li, X., Wang, T., Jiang, H., Ren, Q., Jiao, Y., Sawa, A., Moran, T., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708452105 · Cited by 279
Widespread Nitration of Pathological Inclusions in Neurodegenerative Synucleinopathies
Duda, J. E., Giasson, B. I., Chen, Q., Gur, T. L., Hurtig, H. I., Stern, M. B., Gollomp, S. M., Ischiropoulos, H., Lee, V. M.-Y., & Trojanowski, J. Q. (2000) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64781-5 · Cited by 277
Neural mechanisms in disorders of movement
Crossman, A. R. (1989) · Comparative Biochemistry and Physiology Part A: Physiology · doi:10.1016/0300-9629(89)90201-6 · Cited by 275
Genetic Analysis of Pathways to Parkinson Disease
Hardy, J. (2010) · Neuron · doi:10.1016/j.neuron.2010.10.014 · Cited by 274
Proteasome inhibition causes nigral degeneration with inclusion bodies in rats
McNaught, K. S. P., Bj??rklund, L. M., Belizaire, R., Isacson, O., Jenner, P., & Olanow, C. W. (2002) · Neuroreport · doi:10.1097/00001756-200208070-00018 · Cited by 274
Self-citationFourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD
Katzenschlager, R., Head, J., Schrag, A., Ben-Shlomo, Y., Evans, A., & Lees, A. J. (2008) · Neurology · doi:10.1212/01.wnl.0000310812.43352.66 · Cited by 271
Manganese intoxication in the rhesus monkey: A clinical, imaging, pathologic, and biochemical study
Olanow, C. W., Good, P. F., Shinotoh, H., Hewitt, K. A., Vingerhoets, F., Snow, B. J., Beal, M. F., Calne, D. B., & Perl, D. P. (1996) · Neurology · doi:10.1212/wnl.46.2.492 · Cited by 264
Parkin negatively regulates JNK pathway in the dopaminergic neurons of Drosophila
Cha, G.-H., Kim, S., Park, J., Lee, E., Kim, M., Lee, S. B., Kim, J. M., Chung, J., & Cho, K. S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500346102 · Cited by 263
Carrier-mediated processes in blood–brain barrier penetration and neural uptake of paraquat
Shimizu, K., Ohtaki, K., Matsubara, K., Aoyama, K., Uezono, T., Saito, O., Suno, M., Ogawa, K., Hayase, N., Kimura, K., et al. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02577-x · Cited by 263
The Impact of Gender and Estrogen on Striatal Dopaminergic Neurotoxicity
MILLER, D. B., ALI, S. F., O'CALLAGHAN, J. P., & LAWS, S. C. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb08230.x · Cited by 262
Absence of nigral degeneration in aged parkin/DJ‐1/PINK1 triple knockout mice
Kitada, T., Tong, Y., Gautier, C. A., & Shen, J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06350.x · Cited by 261
Goetz, C. G., Damier, P., Hicking, C., Laska, E., Müller, T., Olanow, C. W., Rascol, O., & Russ, H. (2007) · Movement Disorders · doi:10.1002/mds.21226 · Cited by 260
Winkler, C., Sauer, H., Lee, C. S., & Björklund, A. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-22-07206.1996 · Cited by 258
IV. MPTP, MPP+ and mitochondrial function
Nicklas, W. J., Youngster, S. K., Kindt, M. V., & Heikkila, R. E. (1987) · Life Sciences · doi:10.1016/0024-3205(87)90299-2 · Cited by 257
Chronic rotenone exposure reproduces Parkinson's disease gastrointestinal neuropathology
Drolet, R. E., Cannon, J. R., Montero, L., & Greenamyre, J. T. (2009) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.06.017 · Cited by 257
Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice
Hwang, D. (2003) · Molecular Brain Research · doi:10.1016/s0169-328x(03)00162-1 · Cited by 257
Ved, R., Saha, S., Westlund, B., Perier, C., Burnam, L., Sluder, A., Hoener, M., Rodrigues, C. M. P., Alfonso, A., Steer, C., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m505910200 · Cited by 255
Kordower, J. H., Herzog, C. D., Dass, B., Bakay, R. A. E., Stansell, J., Gasmi, M., & Bartus, R. T. (2006) · Annals of Neurology · doi:10.1002/ana.21032 · Cited by 252
Lee, C. S., Sauer, H., & Björklund, A. (1996) · Neuroscience · doi:10.1016/0306-4522(95)00571-4 · Cited by 248
Kanda, T., Jackson, M. J., Smith, L. A., Pearce, R. K. B., Nakamura, J., Kase, H., Kuwana, Y., & Jenner, P. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7350 · Cited by 248
Self-citationChronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys
Schneider, J. S., & Kovelowski, C. J. (1990) · Brain Research · doi:10.1016/0006-8993(90)90069-n · Cited by 246
Crossman, A. R. (1990) · Movement Disorders · doi:10.1002/mds.870050203 · Cited by 245
Be´dard, P. J., Paolo, T. D., Falardeau, P., & Boucher, R. (1986) · Brain Research · doi:10.1016/0006-8993(86)90783-3 · Cited by 244
LRRK2 Modulates Vulnerability to Mitochondrial Dysfunction in Caenorhabditis elegans
Saha, S., Guillily, M. D., Ferree, A., Lanceta, J., Chan, D., Ghosh, J., Hsu, C. H., Segal, L., Raghavan, K., Matsumoto, K., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2281-09.2009 · Cited by 243
Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models
Bibbiani, F., Oh, J. D., & Chase, T. N. (2001) · Neurology · doi:10.1212/wnl.57.10.1829 · Cited by 241
Castaño, A., Herrera, A. J., Cano, J., & Machado, A. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00799.x · Cited by 238
Zhang, J., Fitsanakis, V. A., Gu, G., Jing, D., Ao, M., Amarnath, V., & Montine, T. J. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01525.x · Cited by 237
Papa, S. M., Engber, T. M., Kask, A. M., & Chase, T. N. (1994) · Brain Research · doi:10.1016/0006-8993(94)90796-x · Cited by 235
Saporito, M. S., Thomas, B. A., & Scott, R. W. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0751200.x · Cited by 232
McNaught, K. S. P., Belizaire, R., Jenner, P., Olanow, C. W., & Isacson, O. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00296-3 · Cited by 232
Self-citationPartial lesion of the substantia nigra: relation between extent of lesion and rotational behavior
Carman, L. S., Gage, F. H., & Shults, C. W. (1991) · Brain Research · doi:10.1016/0006-8993(91)90835-j · Cited by 230
Stocchi, F., Vacca, L., Ruggieri, S., & Olanow, C. W. (2005) · Archives of Neurology · doi:10.1001/archneur.62.6.905 · Cited by 229
Manson, A. J., Turner, K., & Lees, A. J. (2002) · Movement Disorders · doi:10.1002/mds.10281 · Cited by 226
The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism
Rozas, G., López-Martı́n, E., Guerra, M. J., & Labandeira-Garcı́a, J. L. (1998) · Journal of Neuroscience Methods · doi:10.1016/s0165-0270(98)00078-8 · Cited by 225
Andrew, R., Watson, D. G., Best, S. A., Midgley, J. M., Wenlong, H., & Petty, R. K. H. (1993) · Neurochemical Research · doi:10.1007/bf00978370 · Cited by 225
Anichtchik, O. V., Kaslin, J., Peitsaro, N., Scheinin, M., & Panula, P. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02190.x · Cited by 221
Pearce, R. K. B., Banerji, T., Jenner, P., & David Marsden, C. (1998) · Movement Disorders · doi:10.1002/mds.870130207 · Cited by 220
Self-citationHefti, F., Melamed, E., Sahakian, B. J., & Wurtman, R. J. (1980) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(80)90353-6 · Cited by 218
Shiozaki, S., Ichikawa, S., Nakamura, J., Kitamura, S., Yamada, K., & Kuwana, Y. (1999) · Psychopharmacology · doi:10.1007/s002130051146 · Cited by 216
Drosophila DJ-1 mutants show oxidative stress-sensitive locomotive dysfunction
Park, J., Kim, S. Y., Cha, G.-H., Lee, S. B., Kim, S., & Chung, J. (2005) · Gene · doi:10.1016/j.gene.2005.06.040 · Cited by 213
Meredith, G. E., Totterdell, S., Petroske, E., Santa Cruz, K., Callison, R. C., & Lau, Y.-S. (2002) · Brain Research · doi:10.1016/s0006-8993(02)03514-x · Cited by 212
Lee, C. S. (2000) · Brain · doi:10.1093/brain/123.7.1365 · Cited by 212
Johannessen, J. N., Chiueh, C. C., Burns, R. S., & Markey, S. P. (1985) · Life Sciences · doi:10.1016/0024-3205(85)90062-1 · Cited by 211
Parkin Protects against LRRK2 G2019S Mutant-Induced Dopaminergic Neurodegeneration in Drosophila
Ng, C.-H., Mok, S. Z. S., Koh, C., Ouyang, X., Fivaz, M. L., Tan, E.-K., Dawson, V. L., Dawson, T. M., Yu, F., & Lim, K.-L. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2375-09.2009 · Cited by 211
Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study
Oertel, W. H., Wolters, E., Sampaio, C., Gimenez‐Roldan, S., Bergamasco, B., Dujardin, M., Grosset, D. G., Arnold, G., Leenders, K. L., Hundemer, H., et al. (2006) · Movement Disorders · doi:10.1002/mds.20724 · Cited by 210
Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations
Hauser, R. A., Shulman, L. M., Trugman, J. M., Roberts, J. W., Mori, A., Ballerini, R., & Sussman, N. M. (2008) · Movement Disorders · doi:10.1002/mds.22095 · Cited by 207
Barcia, C., Bahillo, A. S., Fernández‐Villalba, E., Bautista, V., Poza Y Poza, M., Fernández‐Barreiro, A., Hirsch, E. C., & Herrero, M. (2004) · Glia · doi:10.1002/glia.20015 · Cited by 206
Mela, F., Marti, M., Dekundy, A., Danysz, W., Morari, M., & Cenci, M. A. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04456.x · Cited by 205
German, D. C., Dubach, M., Askari, S., Speciale, S. G., & Bowden, D. M. (1988) · Neuroscience · doi:10.1016/0306-4522(88)90320-x · Cited by 200
Kuwahara, T., Koyama, A., Gengyo-Ando, K., Masuda, M., Kowa, H., Tsunoda, M., Mitani, S., & Iwatsubo, T. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m504860200 · Cited by 200
Antioxidants protect PINK1 -dependent dopaminergic neurons in Drosophila
Wang, D., Qian, L., Xiong, H., Liu, J., Neckameyer, W. S., Oldham, S., Xia, K., Wang, J., Bodmer, R., & Zhang, Z. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604661103 · Cited by 197
Modeling PD pathogenesis in mice: Advantages of a chronic MPTP protocol
Meredith, G. E., Totterdell, S., Potashkin, J. A., & Surmeier, D. J. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.04.012 · Cited by 193
Nondopaminergic mechanisms in levodopa‐induced dyskinesia
Brotchie, J. M. (2005) · Movement Disorders · doi:10.1002/mds.20612 · Cited by 192
p53‐dependent neuronal cell death in a DJ‐1‐deficient zebrafish model of Parkinson's disease
Bretaud, S., Allen, C., Ingham, P. W., & Bandmann, O. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04291.x · Cited by 191
Visualization of monoaminergic neurons and neurotoxicity of MPTP in live transgenic zebrafish
Wen, L., Wei, W., Gu, W., Huang, P., Ren, X., Zhang, Z., Zhu, Z., Lin, S., & Zhang, B. (2008) · Developmental Biology · doi:10.1016/j.ydbio.2007.11.012 · Cited by 189
Niswender, C. M., Johnson, K. A., Weaver, C. D., Jones, C. K., Xiang, Z., Luo, Q., Rodriguez, A. L., Marlo, J. E., de Paulis, T., Thompson, A. D., et al. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.049551 · Cited by 188
Rotenone induces non‐specific central nervous system and systemic toxicity
Lapointe, N., St‐Hilaire, M., Martinoli, M., Blanchet, J., Gould, P., Rouillard, C., & Cicchetti, F. (2004) · The FASEB Journal · doi:10.1096/fj.03-0677fje · Cited by 187
Systemic exposure to paraquat and maneb models early Parkinson's disease in young adult rats
Cicchetti, F., Lapointe, N., Roberge-Tremblay, A., Saint-Pierre, M., Jimenez, L., Ficke, B. W., & Gross, R. E. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.03.018 · Cited by 187
Henry, B., Crossman, A. R., & Brotchie, J. M. (1998) · Experimental Neurology · doi:10.1006/exnr.1998.6819 · Cited by 187
Dopamine Gene Therapy for Parkinson’s Disease in a Nonhuman Primate Without Associated Dyskinesia
Jarraya, B., Boulet, S., Scott Ralph, G., Jan, C., Bonvento, G., Azzouz, M., Miskin, J. E., Shin, M., Delzescaux, T., Drouot, X., et al. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000130 · Cited by 186 · cited 1×
“In addition, it is an effective primate model in which to examine neurorestorative strategies such as neurotrophic factors, cell-based therapies and gene therapies (see as examples Iravani et al., 2001; Costa et al., 2001b; Kordower et al., 2006a; Jarraya et al., 2009).”
Background(1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.02218.x · Cited by 186
In vivo alpha-synuclein overexpression in rodents: A useful model of Parkinson's disease?
Chesselet, M.-F. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2007.08.006 · Cited by 186
Caenorhabditis elegans MPP+ Model of Parkinson’s Disease for High-Throughput Drug Screenings
Braungart, E., Gerlach, M., Riederer, P., Baumeister, R., & Hoener, M. C. (2004) · Neurodegenerative Diseases · doi:10.1159/000080983 · Cited by 186
Blandini, F., Levandis, G., Bazzini, E., Nappi, G., & Armentero, M. (2007) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2006.05285.x · Cited by 185
Amantadine reduces levodopa‐induced dyskinesias in parkinsonian monkeys
Blanchet, P. J., Konitsiotis, S., & Chase, T. N. (1998) · Movement Disorders · doi:10.1002/mds.870130507 · Cited by 185
Complex I deficiency and dopaminergic neuronal cell loss in parkin-deficient zebrafish (Danio rerio)
Flinn, L., Mortiboys, H., Volkmann, K., Koster, R. W., Ingham, P. W., & Bandmann, O. (2009) · Brain · doi:10.1093/brain/awp108 · Cited by 184
Pathology associated with sporadic Parkinson’s disease — where does it end?
Braak, H., Müller, C. M., Rüb, U., Ackermann, H., Bratzke, H., de Vos, R. A. I., & Del Tredici, K. (2006) · Parkinson’s Disease and Related Disorders · doi:10.1007/978-3-211-45295-0_15 · Cited by 182
Herkenham, M., Little, M. D., Bankiewicz, K., Yang, S.-C., Markey, S. P., & Johannessen, J. N. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90180-v · Cited by 180
AFQ056 treatment of levodopa‐induced dyskinesias: Results of 2 randomized controlled trials
Berg, D., Godau, J., Trenkwalder, C., Eggert, K., Csoti, I., Storch, A., Huber, H., Morelli‐Canelo, M., Stamelou, M., Ries, V., et al. (2011) · Movement Disorders · doi:10.1002/mds.23616 · Cited by 175
Olanow, C. W., Damier, P., Goetz, C. G., Mueller, T., Nutt, J., Rascol, O., Serbanescu, A., Deckers, F., & Russ, H. (2004) · Clinical Neuropharmacology · doi:10.1097/00002826-200403000-00003 · Cited by 175
C. elegans as a model organism to investigate molecular pathways involved with Parkinson's disease
Harrington, A. J., Hamamichi, S., Caldwell, G. A., & Caldwell, K. A. (2010) · Developmental Dynamics · doi:10.1002/dvdy.22231 · Cited by 174
Cell systems and the toxic mechanism(s) of α-synuclein
Cookson, M. R., & van der Brug, M. (2008) · Experimental Neurology · doi:10.1016/j.expneurol.2007.05.022 · Cited by 173
Monoamine Oxidase‐B Inhibition in the Treatment of Parkinson's Disease
Fernandez, H. H., & Chen, J. J. (2007) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.27.12part2.174s · Cited by 171
Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat
COLPAERT, F. (1987) · Neuropharmacology · doi:10.1016/0028-3908(87)90110-9 · Cited by 169
Lundblad, M., Vaudano, E., & Cenci, M. A. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01632.x · Cited by 168
Ottosson, D. R., Iderberg, H., Li, Q., Dekundy, A., Zhang, J., Li, H., Baishen, R., Danysz, W., Bézard, E., & Cenci, M. A. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.05.001 · Cited by 167
Luchtman, D. W., Shao, D., & Song, C. (2009) · Physiology & Behavior · doi:10.1016/j.physbeh.2009.04.021 · Cited by 167
Lessons from the rotenone model of Parkinson's disease
Greenamyre, J. T., Cannon, J. R., Drolet, R., & Mastroberardino, P.-G. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2009.12.006 · Cited by 166
Sleep disorders in Parkinson's disease: The contribution of the MPTP non-human primate model
Barraud, Q., Lambrecq, V., Forni, C., McGuire, S., Hill, M. P., Bioulac, B. H., Balzamo, E., Bézard, E., Tison, F., & Ghorayeb, I. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.07.019 · Cited by 164
The Role of Glucocerebrosidase Mutations in Parkinson Disease and Lewy Body Disorders
Velayati, A., Yu, W. H., & Sidransky, E. (2010) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-010-0102-x · Cited by 163
α-Synuclein immunopositive Parkinson's disease-related inclusion bodies in lower brain stem nuclei
Braak, E., Sandmann-Keil, D., Rüb, U., Gai, W. P., de Vos, R. A. I., Jansen Steur, E. N. H., Arai, K., & Braak, H. (2001) · Acta Neuropathologica · doi:10.1007/s004010000247 · Cited by 162
Parkinson's disease: insights from pathways
Cookson, M. R., & Bandmann, O. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq167 · Cited by 162
Schneider, J. S., Yuwiler, A., & Markham, C. H. (1987) · Brain Research · doi:10.1016/0006-8993(87)90691-3 · Cited by 160
Loss of LRRK2/PARK8 induces degeneration of dopaminergic neurons in Drosophila
Lee, S. B., Kim, W., Lee, S., & Chung, J. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.04.156 · Cited by 159
Savola, J., Hill, M. P., Engström, M., Merivuori, H., Wurster, S., McGuire, S. G., Fox, S. H., Crossman, A. R., & Brotchie, J. M. (2003) · Movement Disorders · doi:10.1002/mds.10464 · Cited by 159
Inhibitory effects of pesticides on proteasome activity: Implication in Parkinson's disease
Wang, X.-F., Li, S., Chou, A. P., & Bronstein, J. M. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2006.02.012 · Cited by 158
Cited by
Parkinson disease: from pathology to molecular disease mechanisms
Dexter, D. T., & Jenner, P. (2013) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2013.01.018 · Cited by 707
Self-citationHuman symptoms–disease network
Zhou, X., Menche, J., Barabási, A.-L., & Sharma, A. (2014) · Nature Communications · doi:10.1038/ncomms5212 · Cited by 653
Progress towards therapies for disease modification in Parkinson's disease
Vijiaratnam, N., Simuni, T., Bandmann, O., Morris, H. R., & Foltynie, T. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00061-2 · Cited by 419
Johnson, M. E., & Bobrovskaya, L. (2015) · NeuroToxicology · doi:10.1016/j.neuro.2014.12.002 · Cited by 332
Parkinson’s Disease: Pathogenesis and Clinical Aspects
(2018) · Codon Publications eBooks · doi:10.15586/codonpublications.parkinsonsdisease.2018 · Cited by 294
Metadata
- Authors
- Duty, S., & Jenner, P.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2011-10
- Volume
- 164
- Issue
- 4
- Pages
- 1357-1391
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1502339857
- Cited by
- 753
- References
- 399
- FWCI
- 21.22
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.